SLGL
Sol-Gel Technologies Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
9.08
P/S
10.77
EV/EBITDA
18.26
DCF Value
$-59.71
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-39.2%
Net Margin
-31.6%
ROE
-24.3%
ROA
-20.5%
ROIC
-31.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $696.0K | $-3.0M | $-1.07 |
| FY 2025 | $19.4M | $-6.1M | $-2.20 |
| Q3 2025 | $400.0K | $-5.9M | $-2.13 |
| Q2 2025 | $17.3M | $11.6M | $4.17 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
1.27
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.